Leg pain during walking from poor circulation is a different problem from the loss of sensation that can accompany diabetic peripheral neuropathy. STRIDE studied people with both type 2 diabetes and symptomatic peripheral artery disease (PAD). It measured how far participants could walk on a treadmill [1].
What did STRIDE find?
Researchers randomized 396 participants to weekly 1 mg semaglutide injections and 396 to placebo. At 52 weeks, the estimated median maximum distance on a fixed-workload treadmill was 1.21 times baseline in the semaglutide group and 1.08 times baseline in the placebo group. The estimated treatment ratio was 1.13 (95% CI 1.06 to 1.21). The 13% difference describes the comparison of changes from baseline in the two groups. An individual’s improvement can vary [1].
The trial recorded six serious events in five semaglutide participants and nine in six placebo participants that were considered possibly or probably related to treatment. No deaths were attributed to treatment. All participants had type 2 diabetes [1].
How does this fit into PAD care?
ACC and AHA guidance for people with PAD and type 2 diabetes discusses semaglutide and liraglutide to reduce the risk of major cardiovascular events [2][3]. STRIDE addressed a separate question about walking ability in this population. The U.S. Ozempic injection label includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. It does not list improved walking as a separate approved use [4].
Structured exercise, smoking cessation when relevant and management of cardiovascular risk factors remain part of PAD care [2]. A clinician can help you distinguish leg symptoms caused by poor blood flow from other causes and discuss treatment based on your diagnosis.